Videos

In light of clinical data and real-world experience, Jason Porter, MD, considers how he would best select patients with non–small cell lung cancer for IO therapy.

Jason Porter, MD, shares a brief review of the toxicity profile noted on EMPOWER-Lung3 and provides practical advice on how to monitor for and manage adverse events.

Expert perspective on the EMPOWER-Lung3 clinical trial, which combined cemiplimab with chemotherapy as frontline treatment for patients with advanced NSCLC.

Comprehensive insight on the first-line treatment armamentarium available to patients diagnosed with metastatic squamous cell non–small cell lung cancer.

Centering discussion on a patient scenario of metastatic squamous cell NSCLC, expert oncologist Jason Porter, MD, shares his initial impressions on the case.

Brian Jonas, MS. PhD, discusses e-selection as a biomarker in acute myeloid leukemia, and how e-selectin inhibition works along with chemotherapy to decrease tumor growth.

Andreas Saltos, MD, discusses the key discoveries from a phase 1/1B trial of erlotinib and binimetinib in EGFR- and KRAS-mutated non–small cell lung cancer.

Melhem M. Solh, MD, discusses results of a study investigating allogeneic stem cell transplant in patients with myelodysplastic syndrome and acute myeloid leukemia with a TP53 mutation, previously presented at the 2022 Transplantation & Cellular Therapy Meetings.

Dr Joel Neal reviews data from the pivotal clinical trial leading to the FDA approval of mobocertinib for EGFR exon 20-mutated advanced or metastatic lung cancers.

Dr Luis Raez shares his perspectives on ways to manage thrombocytopenia in patients receiving chemotherapy for ES-SCLC treatment.

Dr Piotrowska highlights the currently approved targeted therapies for EGFR exon 20 mutation-positive mNSCLC.

Robert J. Soiffer, MD, discusses the approaches to integrating chimeric antigen receptor T-cell therapy into the treatment of hematologic malignancies.

Dr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.

Dr Jonasch shares his perspective on CheckMate 9ER in the real-world setting and discusses the trial’s health-related quality-of-life outcomes data investigating nivolumab plus cabozantinib in advanced renal cell carcinoma treatment.

Dr Eric Jonasch reviews key efficacy and safety outcomes of the long term follow-up data from CheckMate 9ER and discusses the rationale for evaluating cabozantinib plus nivolumab in patients with advanced RCC.

Dr Eric Jonasch factors that contribute to a patient’s risk status, and how a patient’s risk status impacts front-line treatment choices for patients with advanced RCC.

Eric Jonasch, MD, presents the case of a 72-year-old man with advanced renal cell carcinoma, shares his initial impression.

Martin Dreyling, MD, discusses findings from the phase 3 TRIANGLE study of ibrutinib in patients with mantle cell lymphoma.

Erika P. Hamilton, MD, discusses the next steps following the successful outcomes of the phase 3 DESTINY-Breast03 trial of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Rebecca Silbermann, MD, MMS, discusses the findings of the phase 2 GRIFFIN study which were presented at the 2022 ASH Annual Meeting.

Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.

Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

Charles J. Schneider, MD, FACP, discusses some of the ongoing research examining patients with anal cell carcinoma.

Ghassan K. Abou-Alfa, MD, discusses the LEAP-002 study of pembrolizumab plus lenvatinib vs lenvatinib alone in patients with unresectable hepatocellular carcinoma.

Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.

Maryam Lustberg, MD, MPH, explains how the HER2 low session during the 2022 San Antonio Breast Cancer Symposium.

Thomas James Kipps, MD, PhD, discusses the role of later generation and newer generation burton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia.

Nurse Practitioner Lauren Welch and Dr Michelle Shiller explain if and when they would offer repeat liquid or tissue biopsies to a patient with mNSCLC, and discuss how often patients request “serial biopsies” for detecting treatment response and/or disease progression.

A key opinion leader muses on the treatments she would consider for a patient with mNSCLC, an EGFR exon 20 mutation, and brain metastases.

Shirish M. Gadgeel, MD, MBBS, discusses the results of the KRYSTAL-1 trial trial of adagrasib in patients with KRAS-positive non–small cell lung cancer.